{"id":2181,"date":"2021-11-17T01:37:47","date_gmt":"2021-11-17T01:37:47","guid":{"rendered":"https:\/\/bctasm.wpengine.com\/?page_id=2181"},"modified":"2026-01-22T21:33:39","modified_gmt":"2026-01-22T21:33:39","slug":"the-robert-sutherland-award-for-excellence-in-translational-research","status":"publish","type":"page","link":"https:\/\/bct2026.org\/?page_id=2181","title":{"rendered":"The Robert Sutherland Award"},"content":{"rendered":"\n
\n
\n
\n
\n

The Robert Sutherland Award for Excellence in Translational Research<\/h2>\n\n\n\n

Professor Robert Sutherland AO was the Director of the Cancer Research Program at the Garvan Institute for 27 years, Senior Principal Research Fellow of the National Health and Medical Research Council, and inaugural Director of the Kinghorn Cancer Center in Darlinghurst. He was a former Board member of the Australian Cancer Research Foundation, Cancer Council NSW, and Cancer Institute NSW, and he served on various committees, including the National Health and Medical Research Council. <\/p>\n\n\n\n

In 2010 he received the NSW Premier\u2019s Award for Outstanding Cancer Researcher and was made an Officer of the Order of Australia (AO) \u201cfor distinguished service to medicine as an international contributor to the research of cancer, the development of Australia\u2019s research capacity, and through leadership roles in advisory bodies\u201d.<\/p>\n\n\n\n

Nominations for the 2026 Robert Sutherland Award have now closed.<\/strong><\/p>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n
<\/div>\n<\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

The Robert Sutherland Award recognises Translational Researchers and their achievements and contributions to improved patient outcomes as well as scientific excellence in this field.<\/h3>\n\n\n\n

Professor Sarah-Jane Dawson was the 2025 Recipient of the Robert Sutherland Award for Excellence in Translational Research.<\/em><\/p>\n\n\n\n

<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n

About the Award<\/h2>\n\n\n\n

The recipient will be invited to present a lecture at the 2026 ASM, will receive travel support to attend the ASM, and will also receive a financial contribution of up to $10,000 towards their research or professional development.<\/p>\n\n\n\n

The award is open to Translational Researchers worldwide.<\/p>\n<\/div><\/div>\n\n\n\n

\n
Award Details<\/summary>
\n

The Award is offered annually, and if awarded presented at the ASM. The award will be made at the discretion of the Board.<\/p>\n\n\n\n

    \n
  • The Award will cover the cost of attending the 2026 BCT ASM including return economy class airfares, accommodation for the duration of the ASM and full registration. All travel and registration for the successful applicant will be organised through the ASM Secretariat.<\/li>\n\n\n\n
  • A financial contribution up to $10,000 towards supporting the recipient\u2019s research or professional development. <\/li>\n<\/ul>\n<\/div><\/details><\/div>\n\n\n\n
    Eligibility Criteria<\/summary>
    \n
      \n
    • This award is open to Translational Researchers worldwide who wish to enhance their knowledge of clinical research, in particular breast cancer clinical trials research.<\/li>\n\n\n\n
    • The recipient does not need to be a member of BCT but must be nominated by a Full Member of BCT.<\/li>\n<\/ul>\n<\/div><\/details><\/div>\n\n\n\n
      Awardee Responsibilities<\/summary>
      \n

      The Robert Sutherland Award for Excellence in Translational Research recipient will be invited to present a lecture at the ASM.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

      Selection Process<\/summary>
      \n
        \n
      • Nominations will include a CV and supporting statement from the Nominator\/Referee. The Nominator\/Referee must be a Full Member of BCT.<\/li>\n\n\n\n
      • Nominations are considered by the BCT Awards Committee and awarded at the discretion of BCT Board of Directors.<\/li>\n\n\n\n
      • Nominators will be notified of the outcome of their nomination once the Awards Committee has made its decision.<\/li>\n<\/ul>\n<\/div><\/details><\/div>\n<\/div><\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2181","page","type-page","status-publish","hentry"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/bct2026.org\/index.php?rest_route=\/wp\/v2\/pages\/2181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bct2026.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bct2026.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bct2026.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bct2026.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2181"}],"version-history":[{"count":0,"href":"https:\/\/bct2026.org\/index.php?rest_route=\/wp\/v2\/pages\/2181\/revisions"}],"wp:attachment":[{"href":"https:\/\/bct2026.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}